WA
ATRA icon

Wealth Architects’s Atara Biotherapeutics ATRA Stock Holding History

Wealth Architects’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-531
Closed -$9.21K – 212
2024
Q1 		$9.21K Hold
531
– – ﹤0.01% 210
2023
Q4 		$6.81K Hold
531
– – ﹤0.01% 199
2023
Q3 		$19.6K Hold
531
– – ﹤0.01% 187
2023
Q2 		$21.4K Hold
531
– – ﹤0.01% 192
2023
Q1 		$38.5K Hold
531
– – 0.01% 187
2022
Q4 		$43.5K Hold
531
– – 0.01% 176
2022
Q3 		$50K Buy
+531
New +$59.6K 0.01% 170

Other funds holding ATRA

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Wealth Architects's ATRA Position: Q2 2024 in Review

Wealth Architects sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 531 shares — an estimated $9.21K sold.

Wealth Architects first reported a position in ATRA in Q3 2022 and held it in 7 quarters. The position peaked at $50K in Q3 2022. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

  • Wealth Architects reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Wealth Architects sold 531 Atara Biotherapeutics shares in Q2 2024, an estimated $9.21K.
  • Wealth Architects first reported a position in Atara Biotherapeutics in Q3 2022 and held it in 7 quarters.
  • Wealth Architects's Atara Biotherapeutics position peaked at $50K in Q3 2022.
  • 48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on Wealth Architects's 13F filing for Q2 2024, filed 8 Aug 2024.